Pfizer Inc. announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).
Original Source of Pfizer Discontinues A…
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has completed its acquisition of 100% of Chattem, Inc., which is now a wholly-owned subsidiary of the sanofi-aventis Group.
Original Source of Sanofi-aventis Successfully Completes the Acquisition of Chattem, Inc.
Hospitals in the Middle East are set to benefit from sophisticated electronic clinical decision support following the commercial agreement between First DataBank International (FDB International) and GE Healthcare (GE).
Original Source of Electronic Clinical Decision Support for Middle Eastern Hospitals
A former Novartis sales rep was awarded more than $579,000 by a federal jury, which decided that she was retaliated against for taking maternity leave; a class action suit involving similar claims is nearing trial. Report
Original Source of Ex-Novartis sales rep wins maternity-leave case
The Massachusetts attorney general joined that federal lawsuit accusing Johnson & Johnson of paying kickbacks to push the antipsychotic Risperdal and other drugs into nursing homes. AG Martha Coakley didn’t stop there; however, her office is also investigating other companies that market antipsychotics to nursing homes in the state. At…
You can never accuse the Chinese of thinking small. The latest: A Chinese consortium is planning to build Asia’s largest contract manufacturing base in Beijing. The $120 million project is slated for the Beijing Yizhuang Development Zone, an area that already houses more than 100 biopharma ventures. Contract manufacturing has…
The FDA advises, but Medco Health Solutions activates. The pharmacy benefits manager is urging doctors to screen patients before prescribing certain drugs, including the blood thinner warfarin and breast cancer med tamoxifen. The “personalized medicine” move is designed to target prescriptions to patients who really will benefit from them, saving…
In the wake of two new studies suggesting a link between bisphosphonates and a certain type of bone breakage, the
AstraZeneca is jumping into the branded generics market with a licensing-and-supply deal with India’s Torrent Pharmaceuticals. And like other Big Pharma-generics maker arrangements, this deal will marry AstraZeneca’s brand name with Torrent’s generic products in an effort to boost emerging-markets sales for both. Off-patent drugs tend to sell better in…
Roche and Biogen Idec announced their decision to suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis (RA) programme. The decision follows the recommendation of the independent Ocrelizumab RA & Lupus Data and Safety Monitoring Board (DSMB) based on their assessment of the studies in RA (SCRIPT, FEATURE, FILM and…